The Role of the EKG in Anticancer Drug Development
Completed
- Conditions
- Advanced Cancer
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2011-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 525
- Registration Number
- NCT01462383
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
Phase 1
Completed
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01460498
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Cancers
- Interventions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT01454804
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Completed
- Conditions
- CancerProstate Cancer
- Interventions
- Behavioral: Post-Test QuestionnaireBehavioral: InterviewsBehavioral: Focus Groups
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01447186
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
- Conditions
- Bladder CancerKidney CancerUterus CancerEndometrial CancerSkin CancerColorectal Cancer
- Interventions
- Behavioral: Health and Diet Questionnaire
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2000
- Registration Number
- NCT01447199
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
Phase 2
Active, not recruiting
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT01446133
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
Phase 2
Completed
- Conditions
- LeukemiaMyeloproliferative Diseases
- Interventions
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT01444742
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Biological: Ofatumumab
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT01444716
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
Phase 1
Completed
- Conditions
- Myeloma
- Interventions
- Behavioral: Symptom Questionnaire
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT01440582
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
Phase 2
Active, not recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Behavioral: Nutritional CounselingDietary Supplement: Daily Supplements
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT01439659
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States